On June 1, 2023, Insulet Corporation and Amgen Inc. entered into Amendment Number 21 to the Supply Agreement, dated as of November 21, 2013, between the Company and Amgen, as amended by Amendments 1-20, pursuant to which Insulet manufactures and sells to Amgen customized devices. Pursuant to Amendment 21, the term of the Original Agreement is extended and certain definitions as well as terms and conditions related to manufacturing sites, timing, purchase commitments, qualification requirements, pricing and other matters are amended. In connection with Amendment 21, the Company and Amgen also entered into a Patent Assignment and License Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
174.4 USD | +0.58% | +4.96% | -19.61% |
03-20 | US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady | MT |
03-20 | Insulet Names Ana Maria Chadwick Finance Chief | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.61% | 12.21B | |
-3.79% | 184B | |
-0.84% | 108B | |
-3.75% | 67.8B | |
+3.45% | 51.05B | |
+9.04% | 44.67B | |
+3.40% | 41.78B | |
+3.66% | 26.59B | |
+3.21% | 26.78B | |
+15.23% | 25.86B |
- Stock Market
- Equities
- PODD Stock
- News Insulet Corporation
- Insulet Corporation and Amgen Inc. Enter into Amendment Number 21 to the Supply Agreement